Skip to main content
Top
Published in: Clinical Drug Investigation 10/2006

01-10-2006 | Original Research Article

Treatment of Aphthous Stomatitis with Topical Alchemilla vulgaris in Glycerine

Authors: Dr Ravi Shrivastava, Gareth W. John

Published in: Clinical Drug Investigation | Issue 10/2006

Login to get access

Abstract

Background and objective: Recurrent aphthous ulceration is the most common oral mucosal disease known. It presents as three types: minor (most prevalent), major and herpetiform. However, there are no well established effective and reliable treatments of this condition. Alchemilla vulgaris (Lady’s Mantle) has traditionally been used in oral hygiene and was recently shown to accelerate wound healing when used in combination with glycerine. The objective of this study was to determine whether this combination is effective in the treatment of the most prevalent form of aphthous ulcers.
Methods: An open-label study was conducted in 48 otherwise healthy male and female patients aged 4–44 years to determine the putative healing properties and tolerability of a standard 3% extract of A. vulgaris in glycerine (Aphtarine®) on common minor oral ulcers. Patients with major or herpetiform ulcers were excluded from the study.
Results: Topical application three times daily of Aphtarine® gel to minor mouth ulcers relieved discomfort and produced complete healing in the majority of patients (60.4%) within 2 days and in 75% within 3 days, compared with 10.4% and 33.3%, respectively, without treatment and 15% and 40%, respectively, with commonly available treatments. Most patients appreciated the product’s ease of application, taste and texture. Aphtarine® was well tolerated locally and most patients rated the product good to excellent overall.
Conclusion: Aphtarine® is a safe, well tolerated and highly effective promising new treatment for healing common mouth ulcers.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
go back to reference Ship JA. Recurrent aphthous stomatitis: an update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81(2): 141–7PubMedCrossRef Ship JA. Recurrent aphthous stomatitis: an update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81(2): 141–7PubMedCrossRef
2.
go back to reference Barrons RW. Treatment strategies for recurrent oral aphthous ulcers. Am J Health Syst Pharm 2001; 58(1): 41–50PubMed Barrons RW. Treatment strategies for recurrent oral aphthous ulcers. Am J Health Syst Pharm 2001; 58(1): 41–50PubMed
3.
go back to reference Eisen D, Lynch DP. Selecting topical and systemic agents for recurrent aphthous stomatitis. Cutis 2001; 68(3): 201–6PubMed Eisen D, Lynch DP. Selecting topical and systemic agents for recurrent aphthous stomatitis. Cutis 2001; 68(3): 201–6PubMed
4.
go back to reference Kerr AR, Ship JA. Management strategies for HIV-associated aphthous stomatitis. Am J Clin Dermatol 2003; 4(10): 669–80PubMedCrossRef Kerr AR, Ship JA. Management strategies for HIV-associated aphthous stomatitis. Am J Clin Dermatol 2003; 4(10): 669–80PubMedCrossRef
5.
go back to reference Natah SS, Konttinen YT, Enattah NS, et al. Recurrent aphthous ulcers today: a review of the growing knowledge. Int J Oral Maxillofac Surg 2004; 33(3): 221–34PubMedCrossRef Natah SS, Konttinen YT, Enattah NS, et al. Recurrent aphthous ulcers today: a review of the growing knowledge. Int J Oral Maxillofac Surg 2004; 33(3): 221–34PubMedCrossRef
6.
go back to reference Woo SB, Sonis ST. Recurrent aphthous ulcers: a review of diagnosis and treatment. J Am Dent Assoc 1996; 127(8): 1202–13PubMed Woo SB, Sonis ST. Recurrent aphthous ulcers: a review of diagnosis and treatment. J Am Dent Assoc 1996; 127(8): 1202–13PubMed
7.
8.
go back to reference McBride DR. Management of aphthous ulcers. Am Fam Physician 2000; 62(1): 149–54, 160PubMed McBride DR. Management of aphthous ulcers. Am Fam Physician 2000; 62(1): 149–54, 160PubMed
9.
go back to reference Burgess JA, Johnson BD, Sommers E. Pharmacological management of recurrent oral mucosal ulceration. Drugs 1990; 39(1): 54–65PubMedCrossRef Burgess JA, Johnson BD, Sommers E. Pharmacological management of recurrent oral mucosal ulceration. Drugs 1990; 39(1): 54–65PubMedCrossRef
11.
go back to reference Scully C, Shotts R. Mouth ulcers and other causes of orofacial soreness and pain. BMJ 2000; 321(7254): 162–5PubMedCrossRef Scully C, Shotts R. Mouth ulcers and other causes of orofacial soreness and pain. BMJ 2000; 321(7254): 162–5PubMedCrossRef
12.
13.
go back to reference Ship JA, Chavez EM, Doerr PA, et al. Recurrent aphthous stomatitis. Quintessence Int 2000; 31(2): 95–112PubMed Ship JA, Chavez EM, Doerr PA, et al. Recurrent aphthous stomatitis. Quintessence Int 2000; 31(2): 95–112PubMed
14.
go back to reference Lesclous P, Molko S, Samson J. Aphtes et aphtose buccopharynges. Les Cahiers de l’Assoc Dentaire Francais 2000; 10: 5–9 Lesclous P, Molko S, Samson J. Aphtes et aphtose buccopharynges. Les Cahiers de l’Assoc Dentaire Francais 2000; 10: 5–9
15.
go back to reference Shrivastava R. Non-solid composition for local application. Patent PCT/FR/99/01340. 1999 Shrivastava R. Non-solid composition for local application. Patent PCT/FR/99/01340. 1999
17.
go back to reference van Baare J, Ligtvoet EE, Middelkoop E. Microbiological evaluation of glycerolized cadaveric donor skin. Transplantation 1998; 65(7): 966–70PubMedCrossRef van Baare J, Ligtvoet EE, Middelkoop E. Microbiological evaluation of glycerolized cadaveric donor skin. Transplantation 1998; 65(7): 966–70PubMedCrossRef
18.
go back to reference Smith JL, Bencivengo MM, Kunsch CA. Enterotoxin A synthesis in Staphylococcus aureus: inhibition by glycerol and maltose. J Gen Microbiol 1986; 132(12): 3375–80PubMed Smith JL, Bencivengo MM, Kunsch CA. Enterotoxin A synthesis in Staphylococcus aureus: inhibition by glycerol and maltose. J Gen Microbiol 1986; 132(12): 3375–80PubMed
19.
go back to reference Svanberg M, Birkhed D. Effect of dentifrices containing either xylitol and glycerol or sorbitol on mutans streptococci in saliva. Caries Res 1991; 25(6): 449–53PubMedCrossRef Svanberg M, Birkhed D. Effect of dentifrices containing either xylitol and glycerol or sorbitol on mutans streptococci in saliva. Caries Res 1991; 25(6): 449–53PubMedCrossRef
20.
go back to reference Lu HF, Tsou MF, Lin JG, et al. Ellagic acid inhibits growth and arylamine N-acetyltransferase activity and gene expression in Staphylococcus aureus. In Vivo 2005; 19(1): 195–9PubMed Lu HF, Tsou MF, Lin JG, et al. Ellagic acid inhibits growth and arylamine N-acetyltransferase activity and gene expression in Staphylococcus aureus. In Vivo 2005; 19(1): 195–9PubMed
21.
go back to reference Akiyama H, Fujii K, Yamasaki O, et al. Antibacterial action of several tannins against Staphylococcus aureus. J Antimicrob Chemother 2001; 48(4): 487–91PubMedCrossRef Akiyama H, Fujii K, Yamasaki O, et al. Antibacterial action of several tannins against Staphylococcus aureus. J Antimicrob Chemother 2001; 48(4): 487–91PubMedCrossRef
22.
go back to reference Fraisse D, Carnat A, Carnat AP, et al. Standardization of the aerial parts of Alchemilla. Ann Pharm Fr 1999; 57(5): 401–5PubMed Fraisse D, Carnat A, Carnat AP, et al. Standardization of the aerial parts of Alchemilla. Ann Pharm Fr 1999; 57(5): 401–5PubMed
23.
go back to reference Jonadet M, Meunier MT, Villie F, et al. Flavonoids extracted from Ribes nigrum L. and Alchemilla vulgaris L: 1. In vitro inhibitory activities on elastase, trypsin and chymotrypsin. 2. Angioprotective activities compared in vivo. J Pharmacol 1986; 17(1): 21–7PubMed Jonadet M, Meunier MT, Villie F, et al. Flavonoids extracted from Ribes nigrum L. and Alchemilla vulgaris L: 1. In vitro inhibitory activities on elastase, trypsin and chymotrypsin. 2. Angioprotective activities compared in vivo. J Pharmacol 1986; 17(1): 21–7PubMed
24.
go back to reference Lamaison JL, Carnat A, Petitjean-Freytet C. Tannin content and inhibiting activity of elastase in Rosaceae. Ann Pharm Fr 1990; 48(6): 335–40PubMed Lamaison JL, Carnat A, Petitjean-Freytet C. Tannin content and inhibiting activity of elastase in Rosaceae. Ann Pharm Fr 1990; 48(6): 335–40PubMed
25.
go back to reference Lamaison JL, Carnat A, Petitjean-Freytet C, et al. Quercetin-3-glucuronide, main flavonoid of Alchemilla, Alchemilla xanthochlora Rothm. (Rosaceae). Ann Pharm Fr 1991; 49(4): 186–9PubMed Lamaison JL, Carnat A, Petitjean-Freytet C, et al. Quercetin-3-glucuronide, main flavonoid of Alchemilla, Alchemilla xanthochlora Rothm. (Rosaceae). Ann Pharm Fr 1991; 49(4): 186–9PubMed
26.
go back to reference Heikel H. Contribution to the study of Alchemilla vulgaris [thesis]. Lyon,France: Claude Bernard University, 1995: 1–106 Heikel H. Contribution to the study of Alchemilla vulgaris [thesis]. Lyon,France: Claude Bernard University, 1995: 1–106
27.
go back to reference Jimenez F, Mitts TF, Liu K, et al. Ellagic and tannic acids protect newly synthesized elastic fibers from premature enzymatic degradation in dermal fibroblast cultures. J Invest Dermatol 2006; 126(6): 1272–80PubMedCrossRef Jimenez F, Mitts TF, Liu K, et al. Ellagic and tannic acids protect newly synthesized elastic fibers from premature enzymatic degradation in dermal fibroblast cultures. J Invest Dermatol 2006; 126(6): 1272–80PubMedCrossRef
28.
go back to reference Ashoori F, Suzuki S, Zhou JH, et al. Involvement of lipid peroxidation in necrosis of skin flaps and its suppression by ellagic acid. Plast Reconstr Surg 1994; 94(7): 1027–37PubMedCrossRef Ashoori F, Suzuki S, Zhou JH, et al. Involvement of lipid peroxidation in necrosis of skin flaps and its suppression by ellagic acid. Plast Reconstr Surg 1994; 94(7): 1027–37PubMedCrossRef
29.
go back to reference Murthy KN, Reddy VK, Veigas JM, et al. Study on wound healing activity of Punica granatum peel. J Med Food 2004; 7(2): 256–9PubMedCrossRef Murthy KN, Reddy VK, Veigas JM, et al. Study on wound healing activity of Punica granatum peel. J Med Food 2004; 7(2): 256–9PubMedCrossRef
30.
go back to reference Morikawa K, Nonaka M, Narahara M, et al. Inhibitory effect of quercetin on carrageenan-induced inflammation in rats. Life Sci 2003; 74(6): 709–21PubMedCrossRef Morikawa K, Nonaka M, Narahara M, et al. Inhibitory effect of quercetin on carrageenan-induced inflammation in rats. Life Sci 2003; 74(6): 709–21PubMedCrossRef
31.
go back to reference Rotelli AE, Guardia T, Juarez AO, et al. Comparative study of flavonoids in experimental models of inflammation. Pharmacol Res 2003; 48(6): 601–6PubMedCrossRef Rotelli AE, Guardia T, Juarez AO, et al. Comparative study of flavonoids in experimental models of inflammation. Pharmacol Res 2003; 48(6): 601–6PubMedCrossRef
32.
go back to reference Gomathi K, Gopinath D, Rafiuddin Ahmed M, et al. Quercetin incorporated collagen matrices for dermal wound healing processes in rat. Biomaterials 2003; 24(16): 2767–72PubMedCrossRef Gomathi K, Gopinath D, Rafiuddin Ahmed M, et al. Quercetin incorporated collagen matrices for dermal wound healing processes in rat. Biomaterials 2003; 24(16): 2767–72PubMedCrossRef
33.
go back to reference Skaper SD, Fabris M, Ferrari V, et al. Quercetin protects cutaneous tissue-associated cell types including sensory neurons from oxidative stress induced by glutathione depletion: cooperative effects of ascorbic acid. Free Radic Biol Med 1997; 22(4): 669–78PubMedCrossRef Skaper SD, Fabris M, Ferrari V, et al. Quercetin protects cutaneous tissue-associated cell types including sensory neurons from oxidative stress induced by glutathione depletion: cooperative effects of ascorbic acid. Free Radic Biol Med 1997; 22(4): 669–78PubMedCrossRef
34.
go back to reference Gutierrez-Venegas G, Kawasaki-Cardenas P, Rita Arroyo-Cruz S, et al. Luteolin inhibits lipopolysaccharide actions on human gingival fibroblasts. Eur J Pharmacol 2006; 541: 95–105PubMedCrossRef Gutierrez-Venegas G, Kawasaki-Cardenas P, Rita Arroyo-Cruz S, et al. Luteolin inhibits lipopolysaccharide actions on human gingival fibroblasts. Eur J Pharmacol 2006; 541: 95–105PubMedCrossRef
35.
go back to reference Hougee S, Sanders A, Faber J, et al. Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem Pharmacol 2005; 69(2): 241–8PubMedCrossRef Hougee S, Sanders A, Faber J, et al. Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem Pharmacol 2005; 69(2): 241–8PubMedCrossRef
Metadata
Title
Treatment of Aphthous Stomatitis with Topical Alchemilla vulgaris in Glycerine
Authors
Dr Ravi Shrivastava
Gareth W. John
Publication date
01-10-2006
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 10/2006
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200626100-00003

Other articles of this Issue 10/2006

Clinical Drug Investigation 10/2006 Go to the issue